Malvern, Pa.– Fujirebio Holdings, a subsidiary of H.U. Group Holdings Inc., has announced the acquisition of Plasma Services Group, Inc. (PSG), a U.S.-based supplier of rare and high-quality biological raw materials for the in vitro diagnostics (IVD) and life sciences industries. The transaction was completed by Fujirebio Diagnostics, Inc., but financial terms have not been disclosed.
Founded in 2004, PSG operates from an FDA-registered and ISO-certified facility in Moorestown, New Jersey. The company specializes in the collection, screening, and global distribution of rare biological materials, including sera and other control reagents used in research and manufacturing. PSG is particularly recognized for its expertise in sourcing materials relevant to rare diseases, an area of growing importance for both diagnostics development and therapeutic innovation.
The acquisition aims to strengthen Fujirebio’s position as a reliable provider of critical biological components for the IVD sector. By integrating PSG into its operations, Fujirebio intends to enhance its capacity to supply rare and hard-to-source raw materials to diagnostic companies and research institutions worldwide.
Goki Ishikawa, President and CEO of Fujirebio Holdings, said the deal aligns with the company’s long-term strategy of becoming a leading contract development and manufacturing organization (CDMO) for the diagnostics industry. He emphasized that the combined capabilities of Fujirebio and PSG would deliver greater value to their shared customer base by offering a wider and more consistent supply of specialized materials.
Nichelle Fernandez, President of PSG, called the acquisition a meaningful next step in the company’s evolution. She noted that PSG’s mission to serve customers with care and quality will continue under Fujirebio’s ownership. Fernandez said the partnership will help extend PSG’s global reach while preserving the personalized service that has earned it a strong reputation over the past two decades.
Both companies expressed confidence that their shared commitment to quality and consistency will drive innovation and reliability across the global diagnostics supply chain.
